UCLA test predicts which prostate cancer patients are most likely to develop long-term side effects from radiation therapy

Pentagon temporarily rescinds guidance on testosterone testing for U.S. military

The Pentagon has temporarily rescinded a recently published guidance that would require all military personnel aged 30 and over to receive testosterone level testing to check for deficiencies.

September 11, 2026

Vol.52 No.33

By Claire Marie Porter

In Brief

Amir Iravani joins UCLA Health to lead Theranostics Program

Amir Iravani, a nuclear medicine physician-scientist specializing in molecular imaging and targeted radiopharmaceutical therapies for patients with cancer, has joined UCLA Health where he will serve as director of the Theranostics Program and vice chair of clinical research in the department of nuclear medicine and theranostics.

September 11, 2026

Vol.52 No.33

In Brief

Andrew Hsieh named Larry and Virginia Gordon Endowed Chair in Prostate and Bladder Cancer Research at Fred Hutch

Andrew Hsieh, who serves as the associate director of Fred Hutch’s Human Biology Division, has been named the inaugural holder of the Larry and Virginia Gordon Endowed Chair in Prostate and Bladder Cancer Research.

September 11, 2026

Vol.52 No.33

In Brief

UCLA’s Mina Sedrak receives $3.6M NIH grant to improve recovery and reduce accelerated aging after stem cell transplant

Mina Sedrak, director of the UCLA Center for Cancer and Aging and co-director of Cancer Control and Survivorship Research at the UCLA Health Jonsson Comprehensive Cancer Center, has received a five-year, $3.6 million grant from NIH to develop strategies to improve physical recovery and reduce frailty in older adults following hematopoietic cell transplantation, commonly known as a bone marrow or stem cell transplant.

September 11, 2026

Vol.52 No.33

Clinical Roundup

Traditional prostate cancer risk factors do not predict hormone therapy benefit, UCLA-led study finds

Traditional pathological features used to classify aggressive prostate cancer—such as high-grade disease, cancer extending outside the prostate and cancer involving the seminal vesicles—after surgery do not predict who will benefit more from adding hormone therapy to postoperative radiation, according to a study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center.

August 14, 2026

Vol.52 No.32

Clinical Roundup

Half of prostate cancer focal therapy use falls outside current guideline-supported patient groups, study finds

As focal therapy gains popularity as a less invasive treatment option for some men with prostate cancer, a national study led by researchers at the University of Pittsburgh found that some men may be receiving treatment that is either unnecessary or not aggressive enough for their cancer.

August 14, 2026

Vol.52 No.32

UCLA test predicts which prostate cancer patients are most likely to develop long-term side effects from radiation therapy

YOU MAY BE INTERESTED IN

Pentagon temporarily rescinds guidance on testosterone testing for U.S. military

Amir Iravani joins UCLA Health to lead Theranostics Program

Andrew Hsieh named Larry and Virginia Gordon Endowed Chair in Prostate and Bladder Cancer Research at Fred Hutch

UCLA’s Mina Sedrak receives $3.6M NIH grant to improve recovery and reduce accelerated aging after stem cell transplant

Traditional prostate cancer risk factors do not predict hormone therapy benefit, UCLA-led study finds

Half of prostate cancer focal therapy use falls outside current guideline-supported patient groups, study finds

Renew today!

Subscriber content

Never miss an issue!

Login